病原体疫苗中的模式识别受体激动剂调解抗瘤T细胞交叉启动
Mark Aleynick1,2,3, Judit Svensson-Arvelund2,3, Gvantsa Pantsulaia2,3
1Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Journal for immunotherapy of cancer
|July 24, 2023
概括
病原体疫苗成分可以更有效地激活树突细胞 (DCs),而不是在位疫苗接种 (ISV) 的合成激动剂,导致增强的抗瘤T细胞反应和持久的回归.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 疫苗学 疫苗学 疫苗学
背景情况:
- 癌症免疫疗法依赖于对瘤抗原 (TA) 有反应性的T细胞.
- 在位疫苗接种 (ISV) 通过直接向瘤注射免疫刺激剂来启动T细胞.
- 目前的ISV方法使用Flt3L,放射治疗和合成模式识别受体激动剂 (PRRa),但最佳的DC激活是未知的.
研究的目的:
- 为了确定ISV.最佳树突细胞 (DC) 激活剂.
- 评估病原体衍生的天然PRRa (naPRRa) 作为DC激活的临床级试剂.
- 阐明naPRRa增强T细胞原始化的机制.
主要方法:
- 对naPRRa免疫调节效应进行深入分析.
- 特定PRR的基因编辑来定义分子机制.
- 评估naPRRa组合用于DC激活和T细胞交叉启动在小鼠和人类系统中.
主要成果:
- 疫苗naPRRa比合成PRRa更强大的直流激活剂,增强T细胞交叉激活.
- 一种naPRRa (BCG,PedvaxHIB,狂犬病) 的组合诱导了高级T细胞交叉原始化.
- 与naPRRa一起的ISV导致了内CD8T细胞透,新抗原特异性T细胞和持久的瘤回归的增加.
结论:
- 病原体疫苗成分作为有效的临床级DC激活剂对ISV.
- naPRRa提供了一种有希望的策略,以提高癌症免疫疗法的疗效.
- 这种方法支持将病原体疫苗转化为癌症治疗的早期临床试验.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.5K
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
8.7K
相关概念视频
Tumor Immunotherapy
558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
Vaccinations
44.7K
Overview
44.7K
Cell-mediated Immune Responses
68.9K
Overview
68.9K
Cancer Vaccines
405
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
405
T Cell Activation and Clonal Selection
812
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
812
Immune Response Against Viral Pathogens
826
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
826
